ClinicalTrials.gg
Active, not recruitingNCT07443631Updated Nov 6, 2026

Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device Variants

An interventional study of THS1 (TP18 variant 1) and THS2 (TP18 variant 2) in Smoking, sponsored by Philip Morris Products S.A.. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Philip Morris Products S.A. (part of Philip Morris International) · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Smoking by Philip Morris International — none open to participants now, 2 under way, none of them phase 3. Smoking · Philip Morris International.

Enrollment
13th of 32
108 · median 87
Started
2026
the only one that year
No phase
31 of 36
none open now
Registered
36th of 36
by date

Among the 36 studies in Smoking by Philip Morris International, this one is the 13th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2026, is one of 31 with no phase, and was the 36th registered.

Smoking

1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.

Browse Smoking studies →

Open to participants now

None of the 36 studies in Smoking by Philip Morris International is open now. The open studies under Smoking, anywhere →

Who these studies take

Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies in Smoking by Philip Morris International as a file.
02

Study summary

This is a randomized, controlled, open-label, 6 parallel arms study to assess reduced exposure of biomarkers of exposure (BoE) of selected HPHC in smokers switching to TP18 (a prototype heated tobacco device) or THS relative to smokers who continue smoking CIG after 5 days of confinement period, followed by 2 days of pharmacokinetic (PK) period of single use of THS/TP18 and CIG, and followed by an ambulatory period.

Read the detailed description

This randomized, controlled, open-label study comprises six parallel arms and is designed to evaluate reductions in biomarkers of exposure (BoE) to selected HPHCs in adult smokers switching toTP18 (a prototype heated tobacco device with four variants: THS1, THS2, THS3, THS4) or THS5 relative to smokers who continue smoking CIG after 5 days of confinement period followed by 2 days of pharmacokinetic (PK) period of single use of THS/TP18 and CIG, and followed by an ambulatory period.

During the 5-day confinement period, participants will be randomized to use only their assigned product and will operate their assigned devices (THS1, THS2, THS3, THS4, or THS5) with their corresponding sticks or continue smoking CIG ad libitum (6 arms in total).

In the subsequent 2-day PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. Participants randomized to the CIG arm at Baseline will not participate in this period.

During the ambulatory period, participants randomized to one of the TP18 versions at Baseline will be free to choose and use any TP18 variant at any time, ad libitum. Participants randomized at Baseline to TP18 will continue using THS ad libitum. Participants randomized to the CIG arm will only be smoking cigarettes, ad libitum.

03

Conditions studied

  • Smoking

Browse trials for

Keywords

  • HPHC
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has signed the ICF and understands the information provided in it.
  • Participant is male or female and between 21 and 65 years old (inclusive).
  • Participant has been a smoker for at least 2 years prior to the screening visit and is willing to switch to THS and TP18.
  • Participant has smoked on average ≥10 commercially available CIGs/day over the last 30 days. Smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng/mL).
  • Participant does not plan to quit smoking within the next three months.
  • Participant is available for the entire study period and willing to comply with the study procedures, including product use assignments and periods of abstinence from any nicotine/tobacco-containing products, and willing to adhere to a standardized diet (during confinement period and during overnight stays on Day 30 and Day 60).

Exclusion criteria

Exclusion Criteria:

  • As per the Investigator's judgment, the participant cannot participate in the study for any reason other than medical (e.g., psychological, social reason).
  • Participant is legally incompetent, or physically or mentally incapable of giving consent (e.g., in emergency situations, under guardianship, prisoners).
  • Participant has a health condition which requires medication or any other finding based on available assessments from the Screening period (e.g., safety panel, pulmonary function test, vital signs, physical examination, , and medical history), as determined by the Principal Investigator or designee.
  • Participant experienced within 30 days prior to screening/admission a body temperature >37.9°C or an acute illness (e.g., upper respiratory-tract infection, viral infection, etc.).
  • According to the Investigator's judgment, the participant has medical conditions that require or will require medical intervention (e.g., initiation of treatment, surgery, hospitalization) during the study period, which may interfere with study participation and/or study results.
  • Participant uses medication that aids in smoking cessation.
  • Participant experiences difficulty with venipuncture and/or poor venous access.
  • Participant has a level \< 11.0 g/dL for females and \< 12.0 g/dL for males at the Screening visit.
  • Participant has a positive nitrite urinary test at screening or on admission day (Day -2)
  • Participant has donated blood or received whole blood or blood products within the past 3 months.
  • \< 18.5 kg/m2 or ≥ 32.0 kg/m2.
  • Positive serology test for 1/2, , or HCVa.
  • Participant has a positive alcohol breath test and/or has a history of alcohol disorder that could interfere with their participation in the study.
  • The participant has a positive urine drug test.
  • Participant or one of their family members is a current or former employee of the tobacco industry, manufacturing or distributing e-cigarettes or other nicotine/tobacco-containing products.
  • A participant or a family member is an employee of the site or of any other parties involved in the study.
  • Participant has participated in another clinical study within 30 days or within a period equivalent to five half-lives of the investigational product from that study, whichever is longer. .
  • Participant has been previously screened or enrolled in this study (unless they are alternate subjects).
  • Female participant is pregnant (does not have negative pregnancy tests at screening and/or at admission) or is breastfeeding.
  • For women of only and males: participant does not agree to use an acceptable method of effective .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Other
    THS1

    During the confinement period, participants will use only their assigned product THS 1 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum.

    Other: THS1 (TP18 variant 1)

  • Other
    THS2

    During the confinement period, participants will use only their assigned product THS 2 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum.

    Other: THS2 (TP18 variant 2)

  • Other
    THS3

    During the confinement period, participants will use only their assigned product THS 3 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum.

    Other: THS3 (TP18 variant 3)

  • Other
    THS4

    During the confinement period, participants will use only their assigned product THS 4 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum.

    Other: THS4 (TP18 variant 4)

  • Other
    THS5

    During the confinement period, participants will use only their assigned product THS 5 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they will be continue to use THS5 ad libitum.

    Other: THS5 (THS 3.0 reference device)

  • Other
    CIG

    During the confinement period, participants will use only their usual brand of commercially available CIG ad libitum. This arm will not participate in the PK period and will move directly to the ambulatory period. During the ambulatory period, participants will smoke only cigarettes, ad libitum.

    Other: CIG (Cigarette)

Interventions

  • OtherTHS1 (TP18 variant 1)

    TP18 prototype variant "1" (THS1) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.

  • OtherTHS2 (TP18 variant 2)

    TP18 prototype variant "2" (THS2) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.

  • OtherTHS3 (TP18 variant 3)

    TP18 prototype variant "3" (THS3) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.

  • OtherTHS4 (TP18 variant 4)

    TP18 prototype variant "4" (THS4) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.

  • OtherTHS5 (THS 3.0 reference device)

    THS 3.0 device (reference) and the corresponding tobacco sticks will be provided by the Sponsor. There are two variants of the sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants may choose either variant or both.

  • OtherCIG (Cigarette)

    Current cigarette smokers will use their usual brand of commercially available CIG.

06

What researchers measure

Primary outcomes

  1. 3-hydroxypropyl mercapturic acid (3-HPMA) in Urine (confinement period)

    Concentrations of 3-HPMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured from Day -1 to Day 5.

  2. 2-cyanoethyl mercapturic acid N-acetyl-S-(2-cyanoethyl)-L-cysteine (2-CyEMA) in Urine (confinement period)

    Concentrations of 2-CyEMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured from Day -1 to Day 5.

  3. Monohydroxybutenyl mercapturic acid (MHBMA) in Urine (confinement period)

    Concentrations of MHBMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured from Day -1 to Day 5.

  4. Total N-nitrosonornicotine (total NNN) in Urine (confinement period)

    Concentrations of total NNN measured in 24-hour urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured from Day -1 to Day 5.

  5. Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total NNAL) in Urine (confinement period)

    Concentrations of total NNAL measured in 24-hour urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured from Day -1 to Day 5.

  6. Carboxyhemoglobin (COHb) in Blood (confinement period)

    Carboxyhemoglobin (COHb) is assayed from whole blood and expressed as percentage of the total hemoglobin saturated with carbon monoxide.

    Time frame: Measured from Day -1 to Day 5.

Secondary outcomes

  1. S-phenylmercapturic acid (S-PMA) in Urine (confinement period)

    Concentrations of S-PMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured from Day -1 to Day 5.

  2. 2-hydroxyethylmercapturic acid (2-HEMA) in Urine (confinement period)

    Concentrations of 2-HEMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured from Day -1 to Day 5.

  3. 3-hydroxy-1-methylpropylmercapturic acid (3-HMPMA) in Urine (confinement period)

    Concentrations of 3-HMPMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured from Day -1 to Day 5.

  4. Total 3-hydroxybenzo(a)pyrene (3-OH-B[a]P) in Urine (confinement period)

    Concentrations of 3-OH-B\[a\]P measured in 24-hour urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured from Day -1 to Day 5.

  5. 4-aminobiphenyl (4-ABP) in Urine (confinement period)

    Concentrations of 4-ABP measured in 24-hour urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured from Day -1 to Day 5.

  6. 2-aminonaphtalene (2-NA) in Urine (confinement period)

    Concentrations of 2-NA measured in 24-hour urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured from Day -1 to Day 5.

Other outcomes

  1. Plasma nicotine concentrations [C0h] to [C6h] (pharmacokinetic period)

    To measure the background-corrected plasma nicotine concentrations (C0h) to (C12h)

    Time frame: Measured from Day 6 to Day 7.

  2. Maximum plasma nicotine concentration [Cmax] (pharmacokinetic period)

    To measure the background-corrected maximum plasma nicotine concentration \[Cmax\]

    Time frame: Measured from Day 6 to Day 7.

  3. Area under the plasma nicotine concentration-time curve (pharmacokinetic period)

    To measure the area under the background-corrected plasma nicotine concentration-time curve (AUC) from the start of product use (T0) to the timepoint of last quantifiable concentration \[AUC0-last\] and extrapolated to infinity \[AUC0-infinity\]

    Time frame: Measured from Day 6 to Day 7.

  4. Maximum concentration [Tmax] (pharmacokinetic period)

    To measure the time to the background-corrected maximum concentration \[Tmax\]

    Time frame: Measured from Day 6 to Day 7.

  5. 3-hydroxypropyl mercapturic acid (3-HPMA) in Urine (ambulatory period)

    Concentrations of 3-HPMA measured in spot urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured on Day 30 and Day 60.

  6. 2-cyanoethyl mercapturic acid N-acetyl-S-(2- cyanoethyl)-L-cysteine (2-CyEMA) in Urine (ambulatory period)

    Concentrations of 2-CyEMA measured in spot urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured on Day 30 and Day 60.

  7. Monohydroxybutenyl mercapturic acid (MHBMA) in Urine (ambulatory period)

    Concentrations of MHBMA measured in spot urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured on Day 30 and Day 60.

  8. Total N-nitrosonornicotine (total NNN) in Urine (ambulatory period)

    Concentrations of total NNN measured in spot urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured on Day 30 and Day 60.

  9. Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (ambulatory period)

    Concentrations of total NNAL measured in spot urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured on Day 30 and Day 60.

  10. Carboxyhemoglobin (COHb) in Blood (ambulatory period)

    Carboxyhemoglobin (COHb) is assayed from whole blood and expressed as percentage of the total hemoglobin saturated with carbon monoxide.

    Time frame: Measured on Day 30 and Day 60.

  11. S-phenylmercapturic acid (S-PMA) in Urine (ambulatory period)

    Concentrations of S-PMA measured in spot urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured on Day 30 and Day 60.

  12. 2-hydroxyethylmercapturic acid (2-HEMA) in Urine (ambulatory period)

    Concentrations of 2-HEMA measured in spot urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured on Day 30 and Day 60.

  13. 3-hydroxy-1-methylpropylmercapturic acid (3-HMPMA) in Urine (ambulatory period)

    Concentrations of 3-HMPMA measured in spot urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured on Day 30 and Day 60.

  14. Total 3-hydroxybenzo(a)pyrene (3-OH-B[a]P) in Urine (ambulatory period)

    Concentrations of 3-OH-B\[a\]P measured in spot urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured on Day 30 and Day 60.

  15. 4-aminobiphenyl (4-ABP) in Urine (ambulatory period)

    Concentrations of 4-ABP measured in spot urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured on Day 30 and Day 60.

  16. 2-aminonaphtalene (2-NA) in Urine (ambulatory period)

    Concentrations of 2-NA measured in spot urine and expressed as concentration adjusted for creatinine.

    Time frame: Measured on Day 30 and Day 60.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Jul 2026, 5 months.

Of 56 industry-sponsored interventional studies with no phase under Smoking, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 5 months is above that.

Counting every sponsor, half of 461 studies reached it within 23 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 2, 2026
StartActual
Feb 19, 2026
Primary completionActual
Jul 29, 2026
CompletionEst.
Dec 18, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07443631
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Feb 19, 2026
Primary completion
Jul 29, 2026
Completion
Dec 18, 2026 (estimated)
Last update
Nov 6, 2026

Study contacts

Christelle Haziza, PhD
study chair · Philip Morris Products S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion